The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the prognostic significance of RACGAP1, Ki67, and TOP2A mRNA expression in high-risk early breast cancer.
Kyriaki Pliarchopoulou
No relevant relationships to disclose
Helen Gogas
No relevant relationships to disclose
Christos A. Papadimitriou
No relevant relationships to disclose
Ralph M Wirtz
Employment or Leadership Position - Stratifyer GmbH
Stock Ownership - Stratifyer GmbH
George Kouvatseas
No relevant relationships to disclose
Eleni Timotheadou
No relevant relationships to disclose
Flora Stavridi
No relevant relationships to disclose
Christos Christodoulou
No relevant relationships to disclose
Angelos Koutras
No relevant relationships to disclose
Nikolaos Pisanidis
No relevant relationships to disclose
George E. Pentheroudakis
No relevant relationships to disclose
Dimitris Bafaloukos
No relevant relationships to disclose
Epaminontas Samantas
No relevant relationships to disclose
Konstantine T. Kalogeras
No relevant relationships to disclose
Meletios A. Dimopoulos
No relevant relationships to disclose
Dimitrios G. Pectasides
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose